Literature DB >> 34851506

Ezh2 promotes TRβ lysine methylation-mediated degradation in hepatocellular carcinoma.

Su Chan Park1, Ji Min Lee2.   

Abstract

BACKGROUND: Post-translational modification (PTM) of proteins controls various cellular functions of transcriptional regulators and participates in diverse signal transduction pathways in cancer. The thyroid hormone (triiodothyronine, T3) plays a critical role in metabolic homeostasis via its direct interaction with the thyroid hormone receptor beta (TRβ). TRβ is involved in physiological processes, such as cell growth, differentiation, apoptosis, and maintenance of metabolic homeostasis through transcriptional regulation of target genes.
OBJECTIVE: This study was performed to characterize the specific PTM of TRβ is an active control mechanism for the proteasomal degradation of TRβ in transcriptional signaling pathways in hepatocellular carcinoma cells.
METHODS: Based on a previous study, we predicted that the lysine methyltransferase and methylation sites of TRβ by comparing the amino acid sequences of histone H3 and TRβ. Methyl-acceptor site of TRβ was confirmed by point mutation. TRβ protein stability was evaluated by ubiquitination assay with MG132. For glucose starvation, HepG2 cells were incubated in media without D-glucose. Proliferation-related proteins were detected by western blotting. MicroRNA level and autophagy marker were measured by real-time qPCR.
RESULTS: The presence of enhancer of zeste homolog 2 (Ezh2), a methyltransferase of H3 lysine 27, as a methyltransferase of TRβ also revealed that direct lysine methylation and consequent stimulated protein degradation of TRβ underlies the negative correlation between Ezh2 and TRβ. Notably, glucose starvation significantly increased lysine methylation, and methylated TRβ showed further protein instability leading to an increase in the proliferation and growth of hepatocellular carcinoma cells.
CONCLUSIONS: TRβ functions as a tumor suppressor in various cancers; therefore, we evaluated the effect of TRβ degradation on oncogenesis during glucose starvation. These data clearly define a functional model and provide a link between metabolism and cancer by regulating methyl-dependent protein levels of tumor suppressors. Taken together, maintaining TRβ against methyl-dependent degradation is considered a possible therapeutic target for cancer progression.
© 2021. The Author(s) under exclusive licence to The Genetics Society of Korea.

Entities:  

Keywords:  Hepatocellular carcinoma; Metabolic homeostasis; Post-translational modification; Thyroid hormone; Transcriptional regulator; Tumor suppressor

Mesh:

Substances:

Year:  2021        PMID: 34851506     DOI: 10.1007/s13258-021-01196-8

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  44 in total

1.  Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Princess D Rodriguez; Lauren Cozzens; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Cancer Res       Date:  2020-06-17       Impact factor: 5.852

2.  Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.

Authors:  Yunfeng Bai; Zhuangzhuang Zhang; Lijun Cheng; Ruixin Wang; Xiaoliang Chen; Yifan Kong; Feng Feng; Nihal Ahmad; Lang Li; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2019-05-13       Impact factor: 5.157

Review 3.  Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take.

Authors:  Patricia Altea-Manzano; Alejandro M Cuadros; Lindsay A Broadfield; Sarah-Maria Fendt
Journal:  EMBO Rep       Date:  2020-09-23       Impact factor: 8.807

4.  EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains.

Authors:  Maria C Donaldson-Collier; Stephanie Sungalee; Marie Zufferey; Daniele Tavernari; Natalya Katanayeva; Elena Battistello; Marco Mina; Kyle M Douglass; Timo Rey; Franck Raynaud; Suliana Manley; Giovanni Ciriello; Elisa Oricchio
Journal:  Nat Genet       Date:  2019-01-28       Impact factor: 38.330

5.  Why can insulin resistance be a natural consequence of thyroid dysfunction?

Authors:  Gabriela Brenta
Journal:  J Thyroid Res       Date:  2011-09-19

Review 6.  Combination therapy in combating cancer.

Authors:  Reza Bayat Mokhtari; Tina S Homayouni; Narges Baluch; Evgeniya Morgatskaya; Sushil Kumar; Bikul Das; Herman Yeger
Journal:  Oncotarget       Date:  2017-06-06

Review 7.  Targeting autophagy to overcome drug resistance: further developments.

Authors:  Haocai Chang; Zhengzhi Zou
Journal:  J Hematol Oncol       Date:  2020-11-25       Impact factor: 17.388

8.  H3K27me3-rich genomic regions can function as silencers to repress gene expression via chromatin interactions.

Authors:  Yichao Cai; Ying Zhang; Yan Ping Loh; Jia Qi Tng; Mei Chee Lim; Zhendong Cao; Anandhkumar Raju; Erez Lieberman Aiden; Shang Li; Lakshmanan Manikandan; Vinay Tergaonkar; Greg Tucker-Kellogg; Melissa Jane Fullwood
Journal:  Nat Commun       Date:  2021-01-29       Impact factor: 14.919

9.  Nutrient Deprivation Modulates the Metastatic Potential of Breast Cancer Cells.

Authors:  Naghmeh Ahmadiankia; Mehdi Bagheri; Mozhgan Fazli
Journal:  Rep Biochem Mol Biol       Date:  2019-07

10.  Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.

Authors:  Cole D Davidson; Eric L Bolf; Noelle E Gillis; Lauren M Cozzens; Jennifer A Tomczak; Frances E Carr
Journal:  J Endocr Soc       Date:  2021-06-01
View more
  1 in total

Review 1.  Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor.

Authors:  Na Liu; Rui Ling; Xiang Tang; Yunpeng Yu; Yuepeng Zhou; Deyu Chen
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.